A nanoparticle comprising: a core comprising a metal and/or a semiconductor, preferably gold, and a plurality of ligands covalently linked to the core, wherein the ligands comprise (i) at least one liver-targeting ligand； (ii) at least one payload ligand comprising a bioactive agent； and (iii) at least one dilution ligand comprising a carbohydrate, is provided. Preferably the liver-targeting ligand comprises lactose which is covalently linked to the core via a first linker which preferably comprises -(OCH2CH2)m-(CH2)n- where m = 1 to 10 and n = 1 to 15 and is preferably bound to the core via a terminal sulphur atom. Preferably the payload ligand comprises a therapeutic agent selected from doxorubicin, irinotecan, platinum (II), platinum (IV), temozolomide, carmustine, camptothecin, docetaxel, and sorafenib. Preferably the at least one dilution ligand comprises a monosaccharide, in particular glucose or galactose, which is preferably covalently bound to the core via a third linker which comprises -(CH2)n- where n = 2 to 3, which is preferably bound to the core via a terminal sulphur atom. Preferably the nanoparticle comprises a plurality of ligands comprising (iv) a lactose-containing ligand； (v) a doxorubicin-containing ligand； and (vi) a monosaccharide ligand comprising galactose or glucose. Preferably the nanoparticle is for use in the treatment of a liver disorder in a mammalian subject, in particular hepatocellular carcinoma.L'invention concerne une nanoparticule comprenant : un noyau comprenant un métal et/ou un semi-conducteur； et une pluralité de ligands liés par covalence au noyau, lesdits ligands comprenant : au moins un ligand de ciblage du foie； au moins un ligand de charge utile comprenant un agent bioactif； et au moins un ligand de dilution comprenant un glucide. L'invention concerne également des compositions pharmaceutiques comprenant les nanoparticules, leurs utilisations médicales, notamment dans le traitement et l'imagerie de cancers du foie, et de
